董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lauren Chung | 女 | Director | 53 | 未披露 | 0.0004 | 2026-06-23 |
| Peter O Rourke | 男 | Lead Independent Director | 53 | 未披露 | 0.41 | 2026-06-23 |
| Ben Hwang | 男 | Chairman of the board and Chief Executive Officer and Director | 58 | 230.00万美元 | 未持股 | 2026-06-23 |
| Jack Stover | 男 | Director | 73 | 未披露 | 3.21 | 2026-06-23 |
| Rajesh Asarpota | 男 | Director | 59 | 未披露 | 未持股 | 2026-06-23 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Fred Knechtel | 男 | Chief Financial Officer | 65 | 68.58万美元 | 5.45 | 2026-06-23 |
| Ben Hwang | 男 | Chairman of the board and Chief Executive Officer and Director | 58 | 230.00万美元 | 未持股 | 2026-06-23 |
| Bill McMillan | 男 | Chief Scientific Officer and Head of Research | 75 | 未披露 | 未持股 | 2026-06-23 |
董事简历
中英对照 | 中文 | 英文- Lauren Chung
-
Lauren Chung自2020年4月起担任公司董事。2012年，钟博士创立了Minleigh LLC，并从那时起，她担任其首席执行官，识别，评估和与公司合作投资以及战略，运营和商业机会。钟博士拥有超过20年的梦百合投资管理、投资银行和咨询经验。钟博士是Westpark Capital梦百合研究的常务董事。此前，钟博士是Tokum Capital Management（一家全球梦百合基金，与Perella Weinberg Partners合并）的联合创始人。在此之前，钟博士在RBR Capital，Kingdon Capital和Pequot Capital管理梦百合投资组合。在职业生涯早期，钟博士是公认的在马萨诸塞州总医院/哈佛医学院和波士顿儿童医院进行神经退行性和遗传疾病前沿研究的研究科学家。钟博士出版了许多领先的同行评审的科学期刊。Chung持有Columbia University-College of Physicians&Surgeons神经病理学博士学位，以及Wellesley College生物化学和经济学荣誉学士学位。
Lauren Chung has served as a director since July 2025. Since November 2019, Dr. Chung has served as chief executive officer of MINLEIGH LLC, identifying, evaluating and partnering with companies for investments and strategic, operational, and commercial opportunities, and venture partner at Yozma Group. From May 2017 to November 2019, Dr. Chung was an Equity Research Managing Director at WestPark Capital. From August 2016 to April 2017, Dr. Chung was in equity research at Maxim Group. Previously, Dr. Chung founded and served as chief operating officer and chief compliance officer of Tokum Capital Management, a global healthcare investment fund. Prior to that, she managed healthcare investment portfolios at institutional investment firms. Dr. Chung serves as director of Todos Medical Ltd. Dr. Chung previously served as director of Cure Pharmaceutical Holding Corp from August 2019 until November 2021, UltraSight, Inc from December 2020 to December 2021, and AdiTxt, Inc. from June 2021 until December 2021. Dr. Chung holds a Ph.D. in Neuropathology from Columbia University College of Physicians & Surgeons, an M.B.A from Columbia Business School, and a BA with honors in Biochemistry and Economics from Wellesley College. - Lauren Chung自2020年4月起担任公司董事。2012年，钟博士创立了Minleigh LLC，并从那时起，她担任其首席执行官，识别，评估和与公司合作投资以及战略，运营和商业机会。钟博士拥有超过20年的梦百合投资管理、投资银行和咨询经验。钟博士是Westpark Capital梦百合研究的常务董事。此前，钟博士是Tokum Capital Management（一家全球梦百合基金，与Perella Weinberg Partners合并）的联合创始人。在此之前，钟博士在RBR Capital，Kingdon Capital和Pequot Capital管理梦百合投资组合。在职业生涯早期，钟博士是公认的在马萨诸塞州总医院/哈佛医学院和波士顿儿童医院进行神经退行性和遗传疾病前沿研究的研究科学家。钟博士出版了许多领先的同行评审的科学期刊。Chung持有Columbia University-College of Physicians&Surgeons神经病理学博士学位，以及Wellesley College生物化学和经济学荣誉学士学位。
- Lauren Chung has served as a director since July 2025. Since November 2019, Dr. Chung has served as chief executive officer of MINLEIGH LLC, identifying, evaluating and partnering with companies for investments and strategic, operational, and commercial opportunities, and venture partner at Yozma Group. From May 2017 to November 2019, Dr. Chung was an Equity Research Managing Director at WestPark Capital. From August 2016 to April 2017, Dr. Chung was in equity research at Maxim Group. Previously, Dr. Chung founded and served as chief operating officer and chief compliance officer of Tokum Capital Management, a global healthcare investment fund. Prior to that, she managed healthcare investment portfolios at institutional investment firms. Dr. Chung serves as director of Todos Medical Ltd. Dr. Chung previously served as director of Cure Pharmaceutical Holding Corp from August 2019 until November 2021, UltraSight, Inc from December 2020 to December 2021, and AdiTxt, Inc. from June 2021 until December 2021. Dr. Chung holds a Ph.D. in Neuropathology from Columbia University College of Physicians & Surgeons, an M.B.A from Columbia Business School, and a BA with honors in Biochemistry and Economics from Wellesley College.
- Peter O Rourke
-
Peter O’Rourke自注册声明生效之日起担任我们的董事会主席，该声明是本招股说明书的一部分。自2018年12月以来，O’Rourke先生一直担任TCI Partners的管理合伙人，该公司是一家专注于医疗保健，航空航天和公共部门的咨询公司。从2017年1月至2018年12月，O’Rourke先生担任退伍军人事务部代理秘书兼参谋长。从2015年5月到2016年7月，O’Rourke先生担任咨询公司Calibre Systems，Inc.的负责人。奥鲁克还曾在美国海军和空军服役。O’Rourke先生在诺克斯维尔的田纳西大学获得政治学学士学位，并在美国空军理工学院获得物流和供应链管理理学硕士学位。
Peter O Rourke has served as Lead Independent Director since July 2025. Since December 2018, Mr. O'Rourke has served as Managing Partner at TCI Partners, a consulting firm focused on healthcare, aerospace and the public sector. From November 2020 August 2022, Mr. O'Rourke was President and Director for Western Magnesium, where he created the U.S. operations strategy and team during the successful technology pilot phase of the company, and led enterprise and defense business development, government affairs, and communications. From January 2017 to December 2018, Mr. O'Rourke served as the Acting Secretary and Chief of Staff of the Department of Veteran Affairs. From May 2015 to July 2016, Mr. O'Rourke served as a principal of Calibre Systems, Inc., a consulting firm. Mr. O'Rourke also served in both the U.S. Navy and Air Force. Mr. O'Rourke served as Director for AXIM Biotechnologies from July 2020 to present. AXIM is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests. Mr. O'Rourke received a Bachelor of Arts in Political Science from the University of Tennessee in Knoxville as well as a Master of Science in Logistics and Supply Chain Management from the United States Air Force's Institute of Technology. - Peter O’Rourke自注册声明生效之日起担任我们的董事会主席，该声明是本招股说明书的一部分。自2018年12月以来，O’Rourke先生一直担任TCI Partners的管理合伙人，该公司是一家专注于医疗保健，航空航天和公共部门的咨询公司。从2017年1月至2018年12月，O’Rourke先生担任退伍军人事务部代理秘书兼参谋长。从2015年5月到2016年7月，O’Rourke先生担任咨询公司Calibre Systems，Inc.的负责人。奥鲁克还曾在美国海军和空军服役。O’Rourke先生在诺克斯维尔的田纳西大学获得政治学学士学位，并在美国空军理工学院获得物流和供应链管理理学硕士学位。
- Peter O Rourke has served as Lead Independent Director since July 2025. Since December 2018, Mr. O'Rourke has served as Managing Partner at TCI Partners, a consulting firm focused on healthcare, aerospace and the public sector. From November 2020 August 2022, Mr. O'Rourke was President and Director for Western Magnesium, where he created the U.S. operations strategy and team during the successful technology pilot phase of the company, and led enterprise and defense business development, government affairs, and communications. From January 2017 to December 2018, Mr. O'Rourke served as the Acting Secretary and Chief of Staff of the Department of Veteran Affairs. From May 2015 to July 2016, Mr. O'Rourke served as a principal of Calibre Systems, Inc., a consulting firm. Mr. O'Rourke also served in both the U.S. Navy and Air Force. Mr. O'Rourke served as Director for AXIM Biotechnologies from July 2020 to present. AXIM is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests. Mr. O'Rourke received a Bachelor of Arts in Political Science from the University of Tennessee in Knoxville as well as a Master of Science in Logistics and Supply Chain Management from the United States Air Force's Institute of Technology.
- Ben Hwang
-
Ben C. Hwang，自2012年1月起担任Profusa董事会主席兼首席执行官。在加入Profusa之前，黄博士曾在Life Technologies Corp.（已被赛默飞世尔公司收购）担任过多种领导职务，包括亚太区总裁和qPCR部门负责人。在加入生命科技之前，黄博士是麦肯锡公司的顾问。黄博士在约翰霍普金斯大学获得生物学硕士学位和生物学博士学位。
Ben Hwang has served as Profusa's Chairman of the board and Chief Executive Officer since January 2012. Prior to Profusa, Dr. Hwang served in a variety of leadership roles at Life Technologies Corp. (acquired by Thermo Fisher Scientific, Inc.), including President of the Asia Pacific Region and Head of the qPCR Division. Prior to joining Life Technology, Dr. Hwang was a consultant with McKinsey & Company. Dr. Hwang received his M.A. in Biology and Ph.D. in Biology from The Johns Hopkins University. - Ben C. Hwang，自2012年1月起担任Profusa董事会主席兼首席执行官。在加入Profusa之前，黄博士曾在Life Technologies Corp.（已被赛默飞世尔公司收购）担任过多种领导职务，包括亚太区总裁和qPCR部门负责人。在加入生命科技之前，黄博士是麦肯锡公司的顾问。黄博士在约翰霍普金斯大学获得生物学硕士学位和生物学博士学位。
- Ben Hwang has served as Profusa's Chairman of the board and Chief Executive Officer since January 2012. Prior to Profusa, Dr. Hwang served in a variety of leadership roles at Life Technologies Corp. (acquired by Thermo Fisher Scientific, Inc.), including President of the Asia Pacific Region and Head of the qPCR Division. Prior to joining Life Technology, Dr. Hwang was a consultant with McKinsey & Company. Dr. Hwang received his M.A. in Biology and Ph.D. in Biology from The Johns Hopkins University.
- Jack Stover
-
Jack Stover，自2016年5月起担任Traws Pharma，Inc.董事会成员。自2021年3月以来，Stover先生自2022年6月起担任NorthView Acquisition Corp.的首席执行官，直至2022年11月辞职时，Stover先生担任纳斯达克型生物技术公司的董事和审计委员会主席。2015年12月至2016年6月，Stover先生担任Interpace诊断集团有限公司（“Interpace”）的临时总裁兼首席执行官。自2005年8月起，他担任Interpace的董事会成员，并于2005年8月至2015年12月担任Interpace审计委员会主席。Stover先生自2024年2月起担任Stero Therapeutics，Inc.的董事会成员。2016年6月至2020年12月，Stover先生担任Interpace的总裁、首席执行官兼董事，该公司于2019年更名为Interpace Biosciences, Inc.。从2016年6月至2016年12月，Stover先生担任Viatar CTC Solutions，Inc.的审计委员会主席和董事会成员。2004年至2008年，他担任首席执行官、总裁兼Antares Pharma, Inc.的董事，该公司是一家上市于美国证券交易所和随后在纳斯达克上市的公众持股专业制药公司。除了其他相关经验外，Stover先生还曾是普华永道会计师事务所（当时是库珀和Lybrand）的合伙人，在新泽西州的生物科学行业部门工作。Stover先生在理海大学获得会计学学士学位，是一名注册会计师。
Jack Stover has served as a director since July 2025. Since November 2018, Mr. Stover has been director, member of the compensation committee, chairman of the audit committee, chairman of the special deal committee and recently Lead Independent Director of Traws Pharma Inc. (TRAW) (formerly Onconova Therapeutics, Inc. (ONTX)) a Nasdaq based novel small molecule anti viral and oncology therapeutics company with products in various clinical trials. Mr. Stover has also been a member of the board of directors of Stero Therapeutics, Inc., a private medical company, since February 2024. Mr. Stover was appointed to the board of directors and chairman of the audit committee of PharmaCyte Biotech, Inc. (PMBC) effective August 15, 2022 and resigned from the board effective November 1, 2022. From June 2016 to November 2020, Mr. Stover served as president, chief executive officer and director of Interpace Biosciences, Inc., (IDXG) a publicly traded small cap life sciences company providing complex molecular analysis for the early diagnosis and treatment of cancer and supporting the development of targeted therapeutics and previously from December 2015 until June 2016, served as interim president and chief executive officer of IDXG. Mr. Stover was also on the board of directors of IDXG from August 2005 until November 2020, and was chairman of the audit committee from August 2005 until December 2015. From June 2016 to December 2016, Mr. Stover was chairman of the audit committee and a member of the board of directors of Viatar CTC Solutions, Inc. From 2004 to 2008, he served as chief executive officer, president and director of Antares Pharma, Inc., a publicly held specialty pharmaceutical company then listed on the American Stock Exchange. In addition to other relevant experience, Mr. Stover was also formerly a partner with PricewaterhouseCoopers (then Coopers and Lybrand), working in the bioscience industry division in Pennsylvania and New Jersey. Mr. Stover received his B.A. in Accounting from Lehigh University and is a Certified Public Accountant. - Jack Stover，自2016年5月起担任Traws Pharma，Inc.董事会成员。自2021年3月以来，Stover先生自2022年6月起担任NorthView Acquisition Corp.的首席执行官，直至2022年11月辞职时，Stover先生担任纳斯达克型生物技术公司的董事和审计委员会主席。2015年12月至2016年6月，Stover先生担任Interpace诊断集团有限公司（“Interpace”）的临时总裁兼首席执行官。自2005年8月起，他担任Interpace的董事会成员，并于2005年8月至2015年12月担任Interpace审计委员会主席。Stover先生自2024年2月起担任Stero Therapeutics，Inc.的董事会成员。2016年6月至2020年12月，Stover先生担任Interpace的总裁、首席执行官兼董事，该公司于2019年更名为Interpace Biosciences, Inc.。从2016年6月至2016年12月，Stover先生担任Viatar CTC Solutions，Inc.的审计委员会主席和董事会成员。2004年至2008年，他担任首席执行官、总裁兼Antares Pharma, Inc.的董事，该公司是一家上市于美国证券交易所和随后在纳斯达克上市的公众持股专业制药公司。除了其他相关经验外，Stover先生还曾是普华永道会计师事务所（当时是库珀和Lybrand）的合伙人，在新泽西州的生物科学行业部门工作。Stover先生在理海大学获得会计学学士学位，是一名注册会计师。
- Jack Stover has served as a director since July 2025. Since November 2018, Mr. Stover has been director, member of the compensation committee, chairman of the audit committee, chairman of the special deal committee and recently Lead Independent Director of Traws Pharma Inc. (TRAW) (formerly Onconova Therapeutics, Inc. (ONTX)) a Nasdaq based novel small molecule anti viral and oncology therapeutics company with products in various clinical trials. Mr. Stover has also been a member of the board of directors of Stero Therapeutics, Inc., a private medical company, since February 2024. Mr. Stover was appointed to the board of directors and chairman of the audit committee of PharmaCyte Biotech, Inc. (PMBC) effective August 15, 2022 and resigned from the board effective November 1, 2022. From June 2016 to November 2020, Mr. Stover served as president, chief executive officer and director of Interpace Biosciences, Inc., (IDXG) a publicly traded small cap life sciences company providing complex molecular analysis for the early diagnosis and treatment of cancer and supporting the development of targeted therapeutics and previously from December 2015 until June 2016, served as interim president and chief executive officer of IDXG. Mr. Stover was also on the board of directors of IDXG from August 2005 until November 2020, and was chairman of the audit committee from August 2005 until December 2015. From June 2016 to December 2016, Mr. Stover was chairman of the audit committee and a member of the board of directors of Viatar CTC Solutions, Inc. From 2004 to 2008, he served as chief executive officer, president and director of Antares Pharma, Inc., a publicly held specialty pharmaceutical company then listed on the American Stock Exchange. In addition to other relevant experience, Mr. Stover was also formerly a partner with PricewaterhouseCoopers (then Coopers and Lybrand), working in the bioscience industry division in Pennsylvania and New Jersey. Mr. Stover received his B.A. in Accounting from Lehigh University and is a Certified Public Accountant.
- Rajesh Asarpota
-
Rajesh Asarpota，他是高级副总裁、首席财务官，于2014年2月加入我们。加入 Questcor公司之前（从2004年5月到2014年2月），他曾担任Life Technologies Corporation的多种财务领导职务。最近，他曾担任Life Technologies公司的财务副总裁，负责提供金融领导，涉及公司的增长战略、供应链效率、预测和分析、并购金融建模。从1992年7月到2004年4月，他担任the General Electric Corporation的多种财务职务。他持有Marquette University的工商管理硕士学位，以及the University of Bombay的商业学士学位。
Rajesh Asarpota, Senior Vice President, Chief Financial Officer, joined in February 2014. Prior to joining Questcor, from May 2004 to February 2014 Mr. Asarpota held various financial leadership roles with Life Technologies Corporation. Most recently, Mr. Asarpota was Vice President, Finance of Life Technologies, where he was responsible for providing financial leadership on the company's growth strategy, supply chain productivity, forecasting and analysis, and financial modeling for mergers and acquisitions. From July 1992 to April 2004 Mr. Asarpota held various financial positions with the General Electric Corporation. Mr. Asarpota holds a M.B.A. from Marquette University and a Bachelor of Commerce from the University of Bombay. - Rajesh Asarpota，他是高级副总裁、首席财务官，于2014年2月加入我们。加入 Questcor公司之前（从2004年5月到2014年2月），他曾担任Life Technologies Corporation的多种财务领导职务。最近，他曾担任Life Technologies公司的财务副总裁，负责提供金融领导，涉及公司的增长战略、供应链效率、预测和分析、并购金融建模。从1992年7月到2004年4月，他担任the General Electric Corporation的多种财务职务。他持有Marquette University的工商管理硕士学位，以及the University of Bombay的商业学士学位。
- Rajesh Asarpota, Senior Vice President, Chief Financial Officer, joined in February 2014. Prior to joining Questcor, from May 2004 to February 2014 Mr. Asarpota held various financial leadership roles with Life Technologies Corporation. Most recently, Mr. Asarpota was Vice President, Finance of Life Technologies, where he was responsible for providing financial leadership on the company's growth strategy, supply chain productivity, forecasting and analysis, and financial modeling for mergers and acquisitions. From July 1992 to April 2004 Mr. Asarpota held various financial positions with the General Electric Corporation. Mr. Asarpota holds a M.B.A. from Marquette University and a Bachelor of Commerce from the University of Bombay.
高管简历
中英对照 | 中文 | 英文- Fred Knechtel
Fred Knechtel，自公司成立起担任公司首席财务官和董事。从2020年1月至2021年1月，Knechtel先生担任Interpace Biosciences，Inc.的首席财务官。从2018年6月至2018年12月，Knechtel先生担任Genewiz，Inc.的首席财务官，截至2018年11月，该公司的私募市场估值为4.43亿美元。从2014年11月至2017年11月，Knechtel先生担任Sims Metal Management的集团首席财务官，目前市值约为25亿美元。从2009年11月到2011年10月，Knechtel先生担任Remy International,Inc.的首席财务官。Knechtel先生获得了石溪大学的工程学士学位和霍夫斯特拉大学的金融学M.B.A。
Fred Knechtel has served as Profusa, Inc.'s Chief Financial Officer since July 2025, and was the Co Founder, Director and CFO of Northview Acquisition Corporation between August 2023 through the closing of the Business Combination in July 2025. From August 2022 to August 2023, Mr. Knechtel served as chief financial officer of DiamiR Biosciences. From January 2020 to January 2021, Mr. Knechtel served as chief financial officer of Interpace Biosciences, Inc. From June 2018 to December 2018, Mr. Knechtel served as chief financial officer of GENEWIZ, Inc. From November 2014 to November 2017, Mr. Knechtel served as group chief financial officer of Sims Metal Management. From November 2009 to October 2014, Mr. Knechtel served as chief financial officer of Remy International, Inc. Mr. Knechtel received a Bachelor of Engineering from Stony Brook University and a M.B.A in Finance from Hofstra University.- Fred Knechtel，自公司成立起担任公司首席财务官和董事。从2020年1月至2021年1月，Knechtel先生担任Interpace Biosciences，Inc.的首席财务官。从2018年6月至2018年12月，Knechtel先生担任Genewiz，Inc.的首席财务官，截至2018年11月，该公司的私募市场估值为4.43亿美元。从2014年11月至2017年11月，Knechtel先生担任Sims Metal Management的集团首席财务官，目前市值约为25亿美元。从2009年11月到2011年10月，Knechtel先生担任Remy International,Inc.的首席财务官。Knechtel先生获得了石溪大学的工程学士学位和霍夫斯特拉大学的金融学M.B.A。
- Fred Knechtel has served as Profusa, Inc.'s Chief Financial Officer since July 2025, and was the Co Founder, Director and CFO of Northview Acquisition Corporation between August 2023 through the closing of the Business Combination in July 2025. From August 2022 to August 2023, Mr. Knechtel served as chief financial officer of DiamiR Biosciences. From January 2020 to January 2021, Mr. Knechtel served as chief financial officer of Interpace Biosciences, Inc. From June 2018 to December 2018, Mr. Knechtel served as chief financial officer of GENEWIZ, Inc. From November 2014 to November 2017, Mr. Knechtel served as group chief financial officer of Sims Metal Management. From November 2009 to October 2014, Mr. Knechtel served as chief financial officer of Remy International, Inc. Mr. Knechtel received a Bachelor of Engineering from Stony Brook University and a M.B.A in Finance from Hofstra University.
- Ben Hwang
Ben C. Hwang，自2012年1月起担任Profusa董事会主席兼首席执行官。在加入Profusa之前，黄博士曾在Life Technologies Corp.（已被赛默飞世尔公司收购）担任过多种领导职务，包括亚太区总裁和qPCR部门负责人。在加入生命科技之前，黄博士是麦肯锡公司的顾问。黄博士在约翰霍普金斯大学获得生物学硕士学位和生物学博士学位。
Ben Hwang has served as Profusa's Chairman of the board and Chief Executive Officer since January 2012. Prior to Profusa, Dr. Hwang served in a variety of leadership roles at Life Technologies Corp. (acquired by Thermo Fisher Scientific, Inc.), including President of the Asia Pacific Region and Head of the qPCR Division. Prior to joining Life Technology, Dr. Hwang was a consultant with McKinsey & Company. Dr. Hwang received his M.A. in Biology and Ph.D. in Biology from The Johns Hopkins University.- Ben C. Hwang，自2012年1月起担任Profusa董事会主席兼首席执行官。在加入Profusa之前，黄博士曾在Life Technologies Corp.（已被赛默飞世尔公司收购）担任过多种领导职务，包括亚太区总裁和qPCR部门负责人。在加入生命科技之前，黄博士是麦肯锡公司的顾问。黄博士在约翰霍普金斯大学获得生物学硕士学位和生物学博士学位。
- Ben Hwang has served as Profusa's Chairman of the board and Chief Executive Officer since January 2012. Prior to Profusa, Dr. Hwang served in a variety of leadership roles at Life Technologies Corp. (acquired by Thermo Fisher Scientific, Inc.), including President of the Asia Pacific Region and Head of the qPCR Division. Prior to joining Life Technology, Dr. Hwang was a consultant with McKinsey & Company. Dr. Hwang received his M.A. in Biology and Ph.D. in Biology from The Johns Hopkins University.
- Bill McMillan
比尔·麦克米兰是创办Profusa的最初推动力——他构建了公司路线图，招募了顶尖人才并获得了种子资金。作为Profusa生物集成传感器和光学阅读器的共同发明者，Bill McMillan是一位生物技术先驱，他的职业生涯跨越了三十多年的下一代诊断和医疗设备技术和产品的开发，最近20年是一名企业家。他是Cepheid，Inc.（纳斯达克股票代码：CPHD）的联合创始人和研发高级副总裁，Cepheid，Inc.是一家开发和商业化易于使用的分子诊断产品的全球领导者。他在圣何塞州立大学获得化学学士学位和微生物学硕士学位，后来成为一名经过认证的公共卫生微生物学家，之后转入医疗技术行业。
Bill McMillan was the initial driving force to start Profusa — he built the company road map, enlisted top talent and secured seed funding. As a co inventor of Profusa's biologically integrated sensor and optical reader, Bill McMillan is a biotech pioneer whose career has spanned more than three decades in the development of next generation diagnostic and medical device technologies and products, the last 20 years as an entrepreneur. He was the co founder and Senior Vice President of Research and Development at Cepheid, Inc. (NASDAQ: CPHD), a global leader in developing and commercializing easy to use molecular diagnostic products. He earned a B.S. in Chemistry and an M.S. in Microbiology from San Jose State University and later became a certified public health microbiologist before moving to the medical technology industry.- 比尔·麦克米兰是创办Profusa的最初推动力——他构建了公司路线图，招募了顶尖人才并获得了种子资金。作为Profusa生物集成传感器和光学阅读器的共同发明者，Bill McMillan是一位生物技术先驱，他的职业生涯跨越了三十多年的下一代诊断和医疗设备技术和产品的开发，最近20年是一名企业家。他是Cepheid，Inc.（纳斯达克股票代码：CPHD）的联合创始人和研发高级副总裁，Cepheid，Inc.是一家开发和商业化易于使用的分子诊断产品的全球领导者。他在圣何塞州立大学获得化学学士学位和微生物学硕士学位，后来成为一名经过认证的公共卫生微生物学家，之后转入医疗技术行业。
- Bill McMillan was the initial driving force to start Profusa — he built the company road map, enlisted top talent and secured seed funding. As a co inventor of Profusa's biologically integrated sensor and optical reader, Bill McMillan is a biotech pioneer whose career has spanned more than three decades in the development of next generation diagnostic and medical device technologies and products, the last 20 years as an entrepreneur. He was the co founder and Senior Vice President of Research and Development at Cepheid, Inc. (NASDAQ: CPHD), a global leader in developing and commercializing easy to use molecular diagnostic products. He earned a B.S. in Chemistry and an M.S. in Microbiology from San Jose State University and later became a certified public health microbiologist before moving to the medical technology industry.